Paper Details

  1. Home
  2. Paper Details

Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.

Author: FukushimaJulia T, HoffAna Oliveira, HoffPaulo Marcelo, JorgeAlexander Augusto de Lima, KulcsarMarco Aurélio Vamondes, LimaJosé Viana, NegrãoMarcelo Vailati, PapadiaCarla, SimãoEduardo Furquim, TavaresMarcos Roberto, de CastroGilberto, de CastronevesLuciana Audi, de FreitasRicardo Miguel Costa

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study reports the authors' experience using sorafenib, a drug that blocks a specific pathway, to treat advanced medullary thyroid carcinoma (MTC).
Paper Details　
Original Abstract of the Article :
Treatment of advanced medullary thyroid carcinoma (MTC) was recently improved with the approval of vandetanib and cabozantinib. However, there is still a need to explore sequential therapy with more than one tyrosine kinase inhibitor (TKI) and to explore alternative therapies when vandetanib and cab...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/thy.2015.0334

データ提供：米国国立医学図書館（NLM）

Sorafenib for Medullary Thyroid Cancer: Exploring New Oasis in the Desert of Treatment

The treatment of advanced medullary thyroid cancer (MTC) has seen some promising developments with the approval of vandetanib and cabozantinib, two tyrosine kinase inhibitors. However, the search for effective treatment options continues, as the need for sequential therapies and alternative treatments persists. This research explores the potential of sorafenib, another tyrosine kinase inhibitor, as a treatment for advanced MTC. The authors share their experience with sorafenib and provide an analysis of its efficacy and safety.

Sorafenib: A New Path in the Desert of MTC Treatment

The study highlights the potential of sorafenib as a treatment option for advanced MTC, particularly when vandetanib and cabozantinib are not available. The authors' findings suggest that sorafenib may be a valuable tool in the arsenal of therapies for this challenging disease.

A Camel's Reminder: The Importance of Continual Research

The desert of cancer research is a vast and ever-changing landscape. This study underscores the importance of ongoing research and exploration of new treatments. By continually seeking new avenues for therapy, we can offer hope and improved outcomes for patients battling challenging diseases.

Dr. Camel's Conclusion

The quest for effective cancer treatments is a constant journey through a vast and unforgiving desert. This research offers a glimmer of hope, highlighting the potential of sorafenib as a valuable tool in the fight against medullary thyroid cancer. By exploring new pathways and embracing innovation, we can make significant strides in improving the lives of cancer patients.

Date :
  1. Date Completed 2016-12-15
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26701095

DOI: Digital Object Identifier

10.1089/thy.2015.0334

Related Literature

Article Analysis
・Effects of cabozantinib (thyroid cancer)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.